マス・スクリーニングによる神経芽細胞腫の治療成績向上

概要

論文の詳細を見る
Comparative clinical studies were made between 23 cases of neuroblastoma treated before the initiation of mass screening test (pre-screening group) and 21 cases treated thereafter (post-screening group). The post-screening group included 12 cases, discovered by the screening at the average age of 8-month-old. Age distribution at diagnosis showed two peaks at the age of 2 and 4-year-old in the pre-screening group and single big peak of less than one-year-old in the post-screening group. Predominant stage by the Japanese Staging of Pediatric Surgeons' Society was IV (70%) in the pre-screening and I (33%) and III (43%) in the post-screening. No gross difference was noted between the two groups as to the site of origin. Resectability (equivalent to PS-I, II and Ilia by UICC classification) and 2 years survival rate were remarkably improved in the post-screening group, from 13% to 57 and from 26% to 76% respectively. Thus, valuableness of our screening system, using urinary VMA and HVA measurement by HPLC was stressed. The disease was detected at the incidence of one out of 5,200 examined infants.
日本小児外科学会の論文
1988-08-20